Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis
Conferences
Briganti, A; Luz, M; Yu, E; Pieczonka, C; Murphy, D; Armstrong, AJ; Hellmis, E; Kretz, T; Spiegelhalder, P; Adorjan, P; Ghadessi, M; Suzuki, H ...
Published in: EUROPEAN UROLOGY
March 2025
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
EUROPEAN UROLOGY
EISSN
1873-7560
ISSN
0302-2838
Publication Date
March 2025
Volume
87
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Briganti, A., Luz, M., Yu, E., Pieczonka, C., Murphy, D., Armstrong, A. J., … Suzuki, H. (2025). Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. In EUROPEAN UROLOGY (Vol. 87).
Briganti, A., M. Luz, E. Yu, C. Pieczonka, D. Murphy, A. J. Armstrong, E. Hellmis, et al. “Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis.” In EUROPEAN UROLOGY, Vol. 87, 2025.
Briganti A, Luz M, Yu E, Pieczonka C, Murphy D, Armstrong AJ, et al. Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. In: EUROPEAN UROLOGY. 2025.
Briganti, A., et al. “Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis.” EUROPEAN UROLOGY, vol. 87, 2025.
Briganti A, Luz M, Yu E, Pieczonka C, Murphy D, Armstrong AJ, Hellmis E, Kretz T, Spiegelhalder P, Adorjan P, Ghadessi M, Verholen F, Suzuki H. Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. EUROPEAN UROLOGY. 2025.
Published In
EUROPEAN UROLOGY
EISSN
1873-7560
ISSN
0302-2838
Publication Date
March 2025
Volume
87
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences